PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

107 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... 6 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
21.
Kullmann, S. et al.: Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care 45, 398-406 (2022)
22.
Küpers, L.K.* et al.: Maternal dietary glycemic index and glycemic load in pregnancy and offspring cord blood DNA methylation. Diabetes Care 45, 1822-1832 (2022)
23.
Ng, K.* et al.: Islet autoantibody type-specific titer thresholds improve stratification of risk of progression to type 1 diabetes in children. Diabetes Care 45, 160-168 (2022)
24.
Rossing, P.* et al.: Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: The FIDELITY analysis. Diabetes Care 45, 2991–2998 (2022)
25.
Schlögl, H. & Stumvoll, M.*: The brains behind SGLT2 inhibition. Diabetes Care 45, 273-275 (2022)
26.
Tobi, E.W.* et al.: Maternal glycemic dysregulation during pregnancy and neonatal blood DNA methylation: Meta-analyses of epigenome-wide association studies. Diabetes Care 45, 614-623 (2022)
27.
Vehik, K.* et al.: Rising hemoglobin A1c in the nondiabetic range predicts progression of type 1 diabetes as well as oral glucose tolerance tests. Diabetes Care 45, 2342-2349 (2022)
28.
Ahuja, V.* et al.: Accuracy of 1-hour plasma glucose during the oral glucose tolerance test in diagnosis of type 2 diabetes in adults: A meta-analysis. Diabetes Care 44, 1062-1069 (2021)
29.
Anand, V.* et al.: Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: Joint analyses of prospective cohort studies in Finland, Germany, Sweden, and the U.S. Diabetes Care 44, 2269-2276 (2021)
30.
Bizzotto, R.* et al.: Processes underlying glycemic deterioration in type 2 diabetes: An IMI DIRECT Study. Diabetes Care 44, 511-518 (2021)
31.
Blonde, L.* et al.: Durable effects of iGlarLixi up to 52 weeks in type 2 diabetes: The LixiLan-G Extension Study. Diabetes Care 44, 774-780 (2021)
32.
Bonifacio, E. et al.: An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care 44, 2260-2268 (2021)
33.
Canouil, M.* et al.: Epigenome-wide association study reveals methylation loci associated with offspring gestational diabetes mellitus exposure and maternal methylome. Diabetes Care 44, 1992-1999 (2021)
34.
Neuwahl, S.J.* et al.: Patient health utility equations for a type 2 diabetes model. Diabetes Care 44, 381-389 (2021)
35.
Pedron, S. ; Kurz, C.F. ; Schwettmann, L. & Laxy, M.: The effect of BMI and type 2 diabetes on socioeconomic status: A two-sample multivariable mendelian randomization study. Diabetes Care 44, 850-852 (2021)
36.
Shao, H.* et al.: Trends in total and out-of-pocket payments for noninsulin glucose-lowering drugs among U.S. adults with large-employer private health insurance from 2005 to 2018. Diabetes Care 44, 925-934 (2021)
37.
Shao, H. et al.: Trends in total and out-of-pocket payments for insulin among privately insured U.S. adults with diabetes from 2005 to 2018. Diabetes Care 44, e1-e3 (2021)
38.
Sujana, C. et al.: Natriuretic peptides and risk of type 2 diabetes: Results from the biomarkers for cardiovascular risk assessment in Europe (BiomarCaRE) consortium. Diabetes Care 44, 2527-2535 (2021)
39.
Addala, A.* et al.: A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: A transatlantic comparison. Diabetes Care 44, 133-140 (2020)
40.
Garvey, W.T.* et al.: Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care 43, 1085-1093 (2020)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... 6 ... ▶▶ ▶▮